Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MBio Diagnostics, Inc. Wins NIH Award for Flu Test Development

Published: Monday, August 01, 2011
Last Updated: Monday, August 01, 2011
Bookmark and Share
MBio Diagnostics, Inc. announces it has received an award from the US National Institutes of Health to detect disease-causing respiratory pathogens in humans.

The five-year, $5.2 million award from NIH’s “Partnerships for Biodefense” program will address two major public health needs: a rapid, inexpensive influenza diagnostic with performance superior to commonly used flu tests; and rapid deployment during public health screening emergencies such as the 2009 H1N1 influenza pandemic or a bioterror event.

According to MBio’s CEO, Chris Myatt, current rapid flu tests aren’t very sensitive - a person who receives a negative result may in fact have influenza. Dr. Myatt noted that during the 2009 pandemic “we saw how rapid flu tests run in clinics were of limited utility. Laboratory based molecular tests provided much better accuracy, but were more expensive and results took days to get back to the patient.” He added that the goal of the NIH-funded program is to develop a nucleic acid-based test that delivers the accuracy of the laboratory diagnostic in an easy-to-use, inexpensive format that can be run while the patient waits. “Enabling the physician to make immediate and appropriate drug decisions not only benefits the patient, it can improve public health by quickly identifying infectious individuals in a population.”

Michael Lochhead, MBio’s VP and award principal investigator, added that the new system will build on the point-of-care diagnostics platform already under development at MBio. “Our multiplexed immunoassay and cell counting devices are working extremely well in pre-commercial field testing as we prepare for regulated clinical trials. The new NIH award will allow MBio to expand our product pipeline to include increasingly important molecular diagnostics applications.” Dr. Lochhead added that the ability to quickly reconfigure the test in response to a new or emerging infectious agent is a major goal of the research program.

The NIH-funded MBio partnership includes globally recognized viral disease experts at the University of California, San Diego, as well as collaborators at the Program for Appropriate Technology in Health (PATH), headquartered in Seattle.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Experimental Therapy For Brain Cancer Could Prevent Drug Resistance
Information from penny-sized microfluidic chips allowed researchers to anticipate resistance to cancer treatment.
3D Printing of Lego Fluidics
Study shows how 3D printing can open up microfluidic technology to a wider audience.
New Method to Preserve Device to Monitor HIV Treatment
Inspired by pregnancy tests, scientists have developed a method to store microfluidic devices for months without refrigeration, giving developing countries an inexpensive and reliable way to treat patients.
Migration Creates Cancer Cell Vulnerabilities
Scientists found that migration can damage cancer cells’ nuclei and DNA, requiring repairs for their survival. The results may open new avenues for targeting metastatic cancer.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!